Details

Autor(en) / Beteiligte

• Ott, Patrick A
• Nazzaro, Matthew
• Pfaff, Kathleen L
• Gjini, Evisa
• Felt, Kristen D
• Wolff, Jacquelyn O
• Buchbinder, Elizabeth I
• Haq, Rizwan
• Sullivan, Ryan J
• Lawrence, Donald P
• McDermott, David F
• Severgnini, Mariano
• Giobbie-Hurder, Anita
• Rodig, Scott J
• Stephen Hodi, F

Titel

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

Ist Teil von

• Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003318

Ort / Verlag

England: BMJ Publishing Group Ltd

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• BackgroundAngiogenic factors promote the growth of tumor vasculature, modulate lymphocyte trafficking into tumors, and inhibit maturation of dendritic cells. We hypothesized that MEDI3617, a human IgG1 kappa monoclonal antibody directed against human angiopoietin-2, in combination with tremelimumab (treme), an IgG2 monoclonal antibody blocking cytotoxic T-lymphocyte-associated protein- (CTLA-4), is safe in patients with advanced melanoma.MethodsIn a phase I, 3+3 dose escalation trial, patients with metastatic or unresectable melanoma received treme in combination with MEDI3617. The primary objectives of the study were safety and determination of recommended phase II dose (RP2D). The secondary objectives included determination of 6-month and 1-year overall survival and best overall response rate. Immune cell populations and soluble factors were assessed in peripheral blood and metastatic tumors using Fluorescence activated cell sorting (FACS), Luminex, and multiplexed immunofluorescence.ResultsFifteen patients (median age: 62) were enrolled in the study (3 patients in cohort 1: treme at 10 mg/kg and MEDI3617 at 200 mg; and 12 patients in cohort 2: treme at 10 mg/kg and MEDI3617 at 600 mg). The most common all-grade treatment-related adverse events were rash, pruritus, fatigue, and extremity edema. No dose-limiting toxicities were observed. Cohort 2 was determined to be the RP2D. There were no patients with confirmed immune-related complete response or immune-related partial response. Six of 15 patients had immune-related stable disease, resulting in a disease control rate of 0.40 (95% CI 0.16 to 0.68). An increase in frequencies of circulating inducible T-cell costimulator (ICOS)+ and human leukocyte antigen (HLA)-DR+ CD4+ and CD8+ T cells and production of Interleukin-2 and Interleukin-10 was observed post therapy.ConclusionsTremelimumab in combination with MEDI3617 is safe in patients with advanced melanoma. Angiopoietin-2 inhibition in combination with immune checkpoint inhibition warrants further exploration.Trial registration numberNCT02141542.